InvestorsHub Logo
Followers 38
Posts 1638
Boards Moderated 0
Alias Born 01/23/2014

Re: pennyfinder post# 172

Wednesday, 01/06/2016 8:04:01 PM

Wednesday, January 06, 2016 8:04:01 PM

Post# of 2139
$CTRV Reports positive results regarding CMX157's significantly enhanced potency against hepatitis B virus (HBV), now determined to be 97-fold compared to tenofovir (TFV), based on state-of-the-art in vitro studies.

97-fold compared to 60-fold back in Oct 2015 as stated in their press release.

CMX157 is ph-2 ready! IND and ph-2 NEWS anyday from now.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HEPA News